Belantamab Mafadotin Maintenance Therapy
Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma
What will happen during the trial?
Primary Objective:
To determine the safety and tolerability of belantamab maintenance therapy after auto-HCT.
Secondary Objectives:
To estimate the complete remission rate (CRR) as defined by the International Myeloma Working Group (IMWG) criteria (Appendix A.) within 9 months post salvage autotransplant with single agent belantamab mafodotin maintenance therapy starting approximately 3 months post salvage auto-transplant in patients with relapsed myeloma.
To evaluate progression-free survival (PFS) and overall survival (OS) (from the data of initiation of maintenance therapy assessed up to 2 years)
To discover the impact of belantamab mafodotin on graft function and immune reconstitution.
• To assess minimal residual disease status (FDA approved MRD assay by flow cytometry - MRD measured down to 1 in 1 million cells, <106) after at 6 months and 1, 2, and 3 years after initiation of maintenance therapy.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 20 patients (estimated)
- Sponsors
- MD Anderson Cancer Center
- Tags
- Antibody Drug Conjugate (ADC), B-Cell Maturation Antigen (BCMA), Post-Autologous Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1218
- NCT Identifier
- NCT05065047
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.